/**
 * Prior authorization criteria, transcribed from published Navitus forms.
 *
 * Navitus publishes 438 drug-specific commercial PA forms, and each one is a
 * numbered decision tree with explicit transitions ("If this option, go to
 * #7") and explicit terminal outcomes carrying approval durations ("Form
 * complete here. (Approve - 4 months)").
 *
 * That structure is the reason this project can claim its PA decisions are
 * correct rather than plausible. Step numbers below are preserved exactly as
 * printed, so a reviewer can open the PDF and check step 7 against step 7.
 *
 * Encoded by hand rather than scraped: these are clinical rules, and a parser
 * that silently mis-reads one produces a confidently wrong denial. Three trees
 * are transcribed in full; the remaining forms are catalogued with their
 * document IDs so the coverage gap is visible rather than papered over.
 */

export type PredicateId =
  | "request.conditionIs"
  | "request.conditionRoutes"
  | "request.answerYes"
  | "request.selectedAny"
  | "prescriber.specialtyIs"
  | "member.hasDiagnosis"
  | "member.hasTrialOf"
  | "member.ageBetween"
  | "member.weightBelowKg"
  | "always";

export interface CriteriaBranch {
  outcome: "step" | "approve" | "deny";
  step?: number;
  days?: number;
  reason?: string;
}

export interface CriteriaStepDef {
  /** The step number exactly as printed on the published form. */
  step: number;
  question: string;
  predicate: PredicateId;
  args?: Record<string, unknown>;
  /** Options presented on the form, shown in the reviewer console. */
  options?: string[];
  yes: CriteriaBranch;
  no: CriteriaBranch;
  citation: string;
}

export interface CriteriaTreeDef {
  id: string;
  name: string;
  scopeLabel: string;
  /** Drug name patterns this tree governs. */
  drugPatterns: string[];
  formId: string;
  url: string;
  defaultApprovalDays: number;
  startStep: number;
  steps: CriteriaStepDef[];
}

const NAVITUS_DOC = (formId: string) =>
  `https://mx.navitus.com/v1/PortalDocuments/Document/${formId}?cultureCode=en-US`;

// ---------------------------------------------------------------------------

const SKYRIZI_FORM = "0ea2bbf9-bd4f-4bd2-8b99-bf893931d2e5";

export const SKYRIZI_SC: CriteriaTreeDef = {
  id: "pa-skyrizi-sc",
  name: "SKYRIZI SC",
  scopeLabel: "Risankizumab-rzaa subcutaneous",
  drugPatterns: ["SKYRIZI"],
  formId: SKYRIZI_FORM,
  url: NAVITUS_DOC(SKYRIZI_FORM),
  defaultApprovalDays: 122,
  startStep: 4,
  steps: [
    {
      step: 4,
      question: "What condition is the product being used for?",
      predicate: "request.conditionIs",
      args: { condition: "plaque-psoriasis-initial" },
      options: [
        "Initial therapy for plaque psoriasis (PsO)",
        "Continuing therapy for plaque psoriasis (PsO)",
        "Psoriatic arthritis (PsA)",
        "Initial therapy for Crohn's disease (CD)",
        "Continuing therapy for Crohn's disease (CD)",
        "Initial therapy for ulcerative colitis (UC)",
        "Continuing therapy for ulcerative colitis (UC)",
        "None of the above",
      ],
      yes: { outcome: "step", step: 5 },
      no: {
        outcome: "deny",
        reason:
          "The requested indication is not among the conditions this criteria set covers. Form complete here (Deny).",
      },
      citation: "SKYRIZI SC prior authorization form, step 4",
    },
    {
      step: 5,
      question: "Is the medication prescribed by a dermatologist?",
      predicate: "prescriber.specialtyIs",
      args: { specialties: ["Dermatology"] },
      yes: { outcome: "step", step: 6 },
      no: {
        outcome: "deny",
        reason:
          "Skyrizi for plaque psoriasis must be prescribed by a dermatologist.",
      },
      citation: "SKYRIZI SC prior authorization form, step 5",
    },
    {
      step: 6,
      question:
        "The member has a diagnosis of at least ONE of the following: moderate to severe plaque psoriasis with 10% or greater body surface involvement and significant functional disability, or debilitating palmoplantar psoriasis.",
      predicate: "request.selectedAny",
      args: {
        field: "diagnosisCriteria",
        options: [
          "moderate-severe-pso-10pct-bsa",
          "debilitating-palmoplantar-psoriasis",
        ],
      },
      options: [
        "Moderate to severe plaque psoriasis (PsO) with greater than or equal to 10% body surface involvement AND significant functional disability",
        "Debilitating palmoplantar psoriasis (PP)",
        "None of the above",
      ],
      yes: { outcome: "step", step: 7 },
      no: {
        outcome: "deny",
        reason:
          "No qualifying diagnosis was documented. Documentation is required to be submitted for an approval.",
      },
      citation: "SKYRIZI SC prior authorization form, step 6",
    },
    {
      step: 7,
      question:
        "The member has had a trial of ONE of the following which was ineffective or not tolerated: a minimum of 15 sessions of phototherapy, methotrexate at a minimum dose of 15 mg per week, or acitretin.",
      predicate: "member.hasTrialOf",
      args: {
        drugPatterns: ["methotrexate", "acitretin", "SORIATANE"],
        alsoAcceptAnswer: "phototherapyTrial",
      },
      options: [
        "Minimum of 15 sessions of phototherapy",
        "Methotrexate (minimum dose of 15 mg/week)",
        "Acitretin (SORIATANE)",
        "None of the above",
      ],
      yes: { outcome: "approve", days: 122 },
      no: { outcome: "step", step: 8 },
      citation:
        "SKYRIZI SC prior authorization form, step 7. Note: a contraindication to or intolerance of methotrexate does not cancel the requirement of a trial of acitretin.",
    },
    {
      step: 8,
      question: "If no, are ALL of the above contraindicated?",
      predicate: "request.answerYes",
      args: { field: "allAlternativesContraindicated" },
      yes: { outcome: "step", step: 9 },
      no: {
        outcome: "deny",
        reason:
          "The member has not tried phototherapy, methotrexate, or acitretin, and they are not all contraindicated. Form complete here (Deny).",
      },
      citation: "SKYRIZI SC prior authorization form, step 8",
    },
    {
      step: 9,
      question: "Please list contraindications to ALL of the above.",
      predicate: "request.answerYes",
      args: { field: "contraindicationsListed" },
      yes: { outcome: "approve", days: 122 },
      no: {
        outcome: "deny",
        reason: "Contraindications were not documented.",
      },
      citation:
        "SKYRIZI SC prior authorization form, step 9. Form complete here (Approve - 4 months).",
    },
  ],
};

// ---------------------------------------------------------------------------

const DUPIXENT_FORM = "7fb39d39-3834-4553-8e03-af0acfb50e19";

export const DUPIXENT: CriteriaTreeDef = {
  id: "pa-dupixent",
  name: "DUPIXENT",
  scopeLabel: "Dupilumab",
  drugPatterns: ["DUPIXENT"],
  formId: DUPIXENT_FORM,
  url: NAVITUS_DOC(DUPIXENT_FORM),
  defaultApprovalDays: 365,
  startStep: 1,
  steps: [
    {
      step: 1,
      question:
        "Please indicate which quantity limit the requested medication is being prescribed for.",
      predicate: "request.selectedAny",
      args: {
        field: "quantityLimitBasis",
        options: [
          "crswnp-copd-2-inj-28d",
          "loading-dose-ad-asthma",
          "maintenance-ad-asthma",
          "eoe-under-40kg",
          "eoe-over-40kg",
          "eoe-12-plus",
        ],
      },
      options: [
        "Allergic fungal rhinosinusitis, CRSwNP, and COPD: up to two injections per 28 days",
        "Loading dose for AD, asthma, CSU, prurigo nodularis, bullous pemphigoid: up to two injections for the first 14 days",
        "Maintenance dose for AD, asthma, CSU, prurigo nodularis, bullous pemphigoid: up to two injections per 28 days",
        "EoE, age 1 to 11 and weighs less than 40 kg: up to two injections per 28 days",
        "EoE, age 1 to 11 and weighs 40 kg or more: up to four injections per 28 days",
        "EoE, age 12 or older: up to four injections per 28 days",
        "None of the above",
      ],
      yes: { outcome: "step", step: 3 },
      no: { outcome: "step", step: 2 },
      citation: "DUPIXENT prior authorization form, step 1",
    },
    {
      step: 2,
      question: "Please provide requested quantity and dosing.",
      predicate: "request.answerYes",
      args: { field: "quantityDosingProvided" },
      yes: { outcome: "step", step: 3 },
      no: {
        outcome: "deny",
        reason: "Requested quantity and dosing were not provided.",
      },
      citation: "DUPIXENT prior authorization form, step 2",
    },
    {
      step: 3,
      question:
        "Provide primary diagnosis including ICD-10 codes. If complex medical circumstances, submit chart documentation with form.",
      predicate: "request.answerYes",
      args: { field: "diagnosisProvided" },
      yes: { outcome: "step", step: 4 },
      no: {
        outcome: "deny",
        reason: "No primary diagnosis with ICD-10 code was provided.",
      },
      citation: "DUPIXENT prior authorization form, step 3",
    },
    {
      step: 4,
      question: "What condition is the product being used for?",
      predicate: "request.conditionIs",
      args: { condition: "atopic-dermatitis-initial" },
      options: [
        "Initial therapy for atopic dermatitis (AD)",
        "Continuing therapy for atopic dermatitis (AD)",
        "Initial therapy for asthma",
        "Continuing therapy for asthma",
        "Initial therapy for CRSwNP",
        "Continuing therapy for CRSwNP",
        "Initial therapy for eosinophilic esophagitis (EoE)",
        "Initial therapy for prurigo nodularis (PN)",
        "Initial therapy for COPD",
        "Initial therapy for chronic spontaneous urticaria (CSU)",
      ],
      yes: { outcome: "step", step: 5 },
      no: {
        outcome: "deny",
        reason:
          "The requested indication is not among the conditions this criteria set covers.",
      },
      citation: "DUPIXENT prior authorization form, step 4",
    },
    {
      step: 5,
      question:
        "Is the member six months of age or older with a diagnosis of moderate to severe atopic dermatitis?",
      predicate: "member.hasDiagnosis",
      args: { codes: ["L20"] },
      yes: { outcome: "step", step: 6 },
      no: {
        outcome: "deny",
        reason:
          "No documented diagnosis of moderate to severe atopic dermatitis (ICD-10 L20).",
      },
      citation: "DUPIXENT prior authorization form, atopic dermatitis initial therapy",
    },
    {
      step: 6,
      question:
        "Has the member had a trial of a medium to high potency topical corticosteroid, or a topical calcineurin inhibitor, which was ineffective or not tolerated?",
      predicate: "member.hasTrialOf",
      args: {
        drugPatterns: [
          "triamcinolone",
          "clobetasol",
          "fluocinonide",
          "betamethasone",
          "mometasone",
          "tacrolimus",
          "pimecrolimus",
        ],
        alsoAcceptAnswer: "topicalTrialDocumented",
      },
      yes: { outcome: "approve", days: 365 },
      no: {
        outcome: "deny",
        reason:
          "No documented trial of a medium to high potency topical corticosteroid or topical calcineurin inhibitor.",
      },
      citation:
        "DUPIXENT prior authorization form, atopic dermatitis step therapy requirement",
    },
  ],
};

// ---------------------------------------------------------------------------

const ADALIMUMAB_FORM = "0a29d17f-498e-4499-bef1-eb8742d7e4c6";

export const ADALIMUMAB: CriteriaTreeDef = {
  id: "pa-adalimumab",
  name: "ADALIMUMAB PRODUCTS",
  scopeLabel: "Adalimumab and adalimumab biosimilars",
  drugPatterns: ["ADALIMUMAB", "HUMIRA", "HYRIMOZ", "YUFLYMA", "HULIO", "ABRILADA"],
  formId: ADALIMUMAB_FORM,
  url: NAVITUS_DOC(ADALIMUMAB_FORM),
  defaultApprovalDays: 365,
  startStep: 1,
  steps: [
    {
      step: 1,
      question:
        "Please indicate which quantity limit the requested medication is being prescribed for.",
      predicate: "request.selectedAny",
      args: {
        field: "quantityLimitBasis",
        options: ["standard-2-inj-28-days", "loading-dose", "hs-weekly"],
      },
      options: [
        "Standard maintenance: up to two injections per 28 days",
        "Loading dose",
        "Hidradenitis suppurativa weekly dosing",
        "None of the above",
      ],
      yes: { outcome: "step", step: 3 },
      no: { outcome: "step", step: 2 },
      citation: "ADALIMUMAB PRODUCTS prior authorization form, step 1",
    },
    {
      step: 2,
      question: "Please provide requested quantity and dosing.",
      predicate: "request.answerYes",
      args: { field: "quantityDosingProvided" },
      yes: { outcome: "step", step: 3 },
      no: {
        outcome: "deny",
        reason: "Requested quantity and dosing were not provided.",
      },
      citation: "ADALIMUMAB PRODUCTS prior authorization form, step 2",
    },
    {
      step: 3,
      question:
        "Provide primary diagnosis including ICD-10 codes. If complex medical circumstances, submit chart documentation with form.",
      predicate: "member.hasDiagnosis",
      args: { codes: ["L40", "M05", "M06", "K50", "K51", "L73", "M45", "H20"] },
      yes: { outcome: "step", step: 4 },
      no: {
        outcome: "deny",
        reason:
          "No qualifying primary diagnosis was documented for an adalimumab product.",
      },
      citation: "ADALIMUMAB PRODUCTS prior authorization form, step 4",
    },
    {
      step: 4,
      question:
        "Is the requested product a preferred adalimumab biosimilar, or has the member failed a preferred biosimilar?",
      predicate: "request.answerYes",
      args: { field: "preferredBiosimilarOrFailure" },
      yes: { outcome: "step", step: 5 },
      no: {
        outcome: "deny",
        reason:
          "A preferred adalimumab biosimilar must be used first. Amendment 7 to contract ETG0013 substitutes biosimilar rebate value for the reference product, and the formulary reflects that preference.",
      },
      citation:
        "ADALIMUMAB PRODUCTS prior authorization form, preferred product requirement",
    },
    {
      step: 5,
      question: "What condition is the product being used for?",
      /*
       * Multi-way branch (form step 5). Continuing CD/UC/PsO/HS require
       * significant improvement + documentation; re-walking conventional
       * therapy on renewals false-Approves non-responders and unlocks specialty
       * POS. RA and other initial branches keep the collapsed conventional-
       * therapy gate at step 6 until those indication trees are fully
       * transcribed.
       */
      predicate: "request.conditionRoutes",
      args: {
        routes: {
          "rheumatoid-arthritis": 6,
          "crohn-initial": 6,
          "ulcerative-colitis-initial": 6,
          "plaque-psoriasis-initial": 6,
          "hidradenitis-suppurativa-initial": 6,
          "crohn-continuing": 27,
          "ulcerative-colitis-continuing": 35,
          "plaque-psoriasis-continuing": 46,
          "hidradenitis-suppurativa-continuing": 54,
        },
      },
      options: [
        "Rheumatoid arthritis (RA)",
        "Initial therapy for Crohn disease (CD)",
        "Continuing therapy for Crohn disease (CD)",
        "Initial therapy for ulcerative colitis (UC)",
        "Continuing therapy for ulcerative colitis (UC)",
        "Initial therapy for plaque psoriasis (PsO)",
        "Continuing therapy for plaque psoriasis (PsO)",
        "Initial therapy for hidradenitis suppurativa (HS)",
        "Continuing therapy for hidradenitis suppurativa (HS)",
        "None of the above",
      ],
      yes: { outcome: "step" },
      no: {
        outcome: "deny",
        reason:
          "The requested indication is not among the conditions this criteria set covers. Form complete here (Deny).",
      },
      citation: "ADALIMUMAB PRODUCTS prior authorization form, step 5",
    },
    {
      step: 6,
      question:
        "Has the member had a trial of a conventional therapy appropriate to the diagnosis, which was ineffective or not tolerated?",
      predicate: "member.hasTrialOf",
      args: {
        drugPatterns: [
          "methotrexate",
          "sulfasalazine",
          "leflunomide",
          "hydroxychloroquine",
          "azathioprine",
          "mesalamine",
          "budesonide",
          "acitretin",
        ],
        alsoAcceptAnswer: "conventionalTherapyTrial",
      },
      yes: { outcome: "approve", days: 365 },
      no: {
        outcome: "deny",
        reason:
          "No documented trial of conventional therapy appropriate to the diagnosis.",
      },
      citation:
        "ADALIMUMAB PRODUCTS prior authorization form, conventional therapy requirement",
    },
    // Continuing Therapy for Crohn's Disease (CD) — form steps 27–30
    {
      step: 27,
      question: "Is the medication prescribed by a gastroenterology specialist?",
      predicate: "prescriber.specialtyIs",
      args: { specialties: ["Gastroenterology"] },
      yes: { outcome: "step", step: 28 },
      no: {
        outcome: "deny",
        reason:
          "Adalimumab continuing therapy for Crohn's disease must be prescribed by a gastroenterology specialist.",
      },
      citation: "ADALIMUMAB PRODUCTS prior authorization form, step 27",
    },
    {
      step: 28,
      question: "Does the member have a diagnosis of Crohn's disease (CD)?",
      predicate: "member.hasDiagnosis",
      args: { codes: ["K50"] },
      yes: { outcome: "step", step: 29 },
      no: {
        outcome: "deny",
        reason: "No documented diagnosis of Crohn's disease (ICD-10 K50).",
      },
      citation: "ADALIMUMAB PRODUCTS prior authorization form, step 28",
    },
    {
      step: 29,
      question: "Has the member demonstrated a significant improvement in their condition?",
      predicate: "request.answerYes",
      args: { field: "significantImprovement" },
      yes: { outcome: "step", step: 30 },
      no: {
        outcome: "deny",
        reason:
          "Significant improvement from pre-treatment baseline was not demonstrated. Form complete here (Deny).",
      },
      citation: "ADALIMUMAB PRODUCTS prior authorization form, step 29",
    },
    {
      step: 30,
      question:
        "Is documentation (written explanation accepted) of improvement within the past year submitted with this request?",
      predicate: "request.answerYes",
      args: { field: "improvementDocumented" },
      yes: { outcome: "approve", days: 365 },
      no: {
        outcome: "deny",
        reason:
          "Documentation of improvement within the past year was not submitted. Form complete here (Deny).",
      },
      citation:
        "ADALIMUMAB PRODUCTS prior authorization form, step 30. Form complete here (Approve - 1 year).",
    },
    // Continuing Therapy for Ulcerative Colitis (UC) — form steps 35–38
    {
      step: 35,
      question: "Does the member have a diagnosis of ulcerative colitis (UC)?",
      predicate: "member.hasDiagnosis",
      args: { codes: ["K51"] },
      yes: { outcome: "step", step: 36 },
      no: {
        outcome: "deny",
        reason: "No documented diagnosis of ulcerative colitis (ICD-10 K51).",
      },
      citation: "ADALIMUMAB PRODUCTS prior authorization form, step 35",
    },
    {
      step: 36,
      question: "Is the medication prescribed by a gastroenterology specialist?",
      predicate: "prescriber.specialtyIs",
      args: { specialties: ["Gastroenterology"] },
      yes: { outcome: "step", step: 37 },
      no: {
        outcome: "deny",
        reason:
          "Adalimumab continuing therapy for ulcerative colitis must be prescribed by a gastroenterology specialist.",
      },
      citation: "ADALIMUMAB PRODUCTS prior authorization form, step 36",
    },
    {
      step: 37,
      question: "Has the member demonstrated a significant improvement in their condition?",
      predicate: "request.answerYes",
      args: { field: "significantImprovement" },
      yes: { outcome: "step", step: 38 },
      no: {
        outcome: "deny",
        reason:
          "Significant improvement from pre-treatment baseline was not demonstrated. Form complete here (Deny).",
      },
      citation: "ADALIMUMAB PRODUCTS prior authorization form, step 37",
    },
    {
      step: 38,
      question:
        "Is documentation (written explanation accepted) of improvement within the past year submitted with this request?",
      predicate: "request.answerYes",
      args: { field: "improvementDocumented" },
      yes: { outcome: "approve", days: 365 },
      no: {
        outcome: "deny",
        reason:
          "Documentation of improvement within the past year was not submitted. Form complete here (Deny).",
      },
      citation:
        "ADALIMUMAB PRODUCTS prior authorization form, step 38. Form complete here (Approve - 1 year).",
    },
    // Continuing Therapy for Plaque Psoriasis (PsO) — form steps 46–49
    {
      step: 46,
      question:
        "Does the member have a diagnosis of plaque psoriasis (PsO) and/or palmoplantar psoriasis (PP)?",
      predicate: "member.hasDiagnosis",
      args: { codes: ["L40"] },
      yes: { outcome: "step", step: 47 },
      no: {
        outcome: "deny",
        reason:
          "No documented diagnosis of plaque psoriasis or palmoplantar psoriasis (ICD-10 L40).",
      },
      citation: "ADALIMUMAB PRODUCTS prior authorization form, step 46",
    },
    {
      step: 47,
      question: "Is the medication prescribed by a dermatologist?",
      predicate: "prescriber.specialtyIs",
      args: { specialties: ["Dermatology"] },
      yes: { outcome: "step", step: 48 },
      no: {
        outcome: "deny",
        reason:
          "Adalimumab continuing therapy for plaque psoriasis must be prescribed by a dermatologist.",
      },
      citation: "ADALIMUMAB PRODUCTS prior authorization form, step 47",
    },
    {
      step: 48,
      question: "Has the member demonstrated a significant improvement in their condition?",
      predicate: "request.answerYes",
      args: { field: "significantImprovement" },
      yes: { outcome: "step", step: 49 },
      no: {
        outcome: "deny",
        reason:
          "Significant improvement from pre-treatment baseline was not demonstrated. Form complete here (Deny).",
      },
      citation: "ADALIMUMAB PRODUCTS prior authorization form, step 48",
    },
    {
      step: 49,
      question:
        "Is documentation (written explanation accepted) of improvement within the past year submitted with this request?",
      predicate: "request.answerYes",
      args: { field: "improvementDocumented" },
      yes: { outcome: "approve", days: 365 },
      no: {
        outcome: "deny",
        reason:
          "Documentation of improvement within the past year was not submitted. Form complete here (Deny).",
      },
      citation:
        "ADALIMUMAB PRODUCTS prior authorization form, step 49. Form complete here (Approve - 1 year).",
    },
    // Continuing Therapy for Hidradenitis Suppurativa (HS) — form steps 54–57
    {
      step: 54,
      question: "Does the member have a diagnosis of hidradenitis suppurativa (HS)?",
      predicate: "member.hasDiagnosis",
      args: { codes: ["L73"] },
      yes: { outcome: "step", step: 55 },
      no: {
        outcome: "deny",
        reason:
          "No documented diagnosis of hidradenitis suppurativa (ICD-10 L73).",
      },
      citation: "ADALIMUMAB PRODUCTS prior authorization form, step 54",
    },
    {
      step: 55,
      question: "Is the medication prescribed by a dermatologist?",
      predicate: "prescriber.specialtyIs",
      args: { specialties: ["Dermatology"] },
      yes: { outcome: "step", step: 56 },
      no: {
        outcome: "deny",
        reason:
          "Adalimumab continuing therapy for hidradenitis must be prescribed by a dermatologist.",
      },
      citation: "ADALIMUMAB PRODUCTS prior authorization form, step 55",
    },
    {
      step: 56,
      question: "Has the member demonstrated a significant improvement in their condition?",
      predicate: "request.answerYes",
      args: { field: "significantImprovement" },
      yes: { outcome: "step", step: 57 },
      no: {
        outcome: "deny",
        reason:
          "Significant improvement from pre-treatment baseline was not demonstrated. Form complete here (Deny).",
      },
      citation: "ADALIMUMAB PRODUCTS prior authorization form, step 56",
    },
    {
      step: 57,
      question:
        "Has the member had improvement based on abscess/nodule size and/or number?",
      predicate: "request.answerYes",
      args: { field: "improvementDocumented" },
      yes: { outcome: "approve", days: 365 },
      no: {
        outcome: "deny",
        reason:
          "Documentation of abscess/nodule improvement was not submitted. Form complete here (Deny).",
      },
      citation:
        "ADALIMUMAB PRODUCTS prior authorization form, step 57. Form complete here (Approve - 1 year).",
    },
  ],
};

export const CRITERIA_TREES: CriteriaTreeDef[] = [SKYRIZI_SC, DUPIXENT, ADALIMUMAB];

export function findTreeForDrug(drugName: string): CriteriaTreeDef | undefined {
  const upper = drugName.toUpperCase();
  return CRITERIA_TREES.find((t) =>
    t.drugPatterns.some((p) => upper.includes(p.toUpperCase())),
  );
}
